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Background: We have recently identified the nuclear hormone receptor RORA (retinoic acid-related orphan
receptor-alpha) as a novel candidate gene for autism spectrum disorder (ASD). Our independent cohort studies
have consistently demonstrated the reduction of RORA transcript and/or protein levels in blood-derived
lymphoblasts as well as in the postmortem prefrontal cortex and cerebellum of individuals with ASD. Moreover, we
have also shown that RORA has the potential to be under negative and positive regulation by androgen and
estrogen, respectively, suggesting the possibility that RORA may contribute to the male bias of ASD. However, little
is known about transcriptional targets of this nuclear receptor, particularly in humans.
Methods: Here we identify transcriptional targets of RORA in human neuronal cells on a genome-wide level using
chromatin immunoprecipitation (ChIP) with an anti-RORA antibody followed by whole-genome promoter array (chip)
analysis. Selected potential targets of RORA were then validated by an independent ChIP followed by quantitative PCR
analysis. To further demonstrate that reduced RORA expression results in reduced transcription of RORA targets, we
determined the expression levels of the selected transcriptional targets in RORA-deficient human neuronal cells, as well
as in postmortem brain tissues from individuals with ASD who exhibit reduced RORA expression.
Results: The ChIP-on-chip analysis reveals that RORA1, a major isoform of RORA protein in human brain, can be
recruited to as many as 2,764 genomic locations corresponding to promoter regions of 2,544 genes across the human
genome. Gene ontology analysis of this dataset of genes that are potentially directly regulated by RORA1 reveals
statistically significant enrichment in biological functions negatively impacted in individuals with ASD, including
neuronal differentiation, adhesion and survival, synaptogenesis, synaptic transmission and plasticity, and axonogenesis,
as well as higher level functions such as development of the cortex and cerebellum, cognition, memory, and spatial
learning. Independent ChIP-quantitative PCR analyses confirm binding of RORA1 to promoter regions of selected
ASD-associated genes, including A2BP1, CYP19A1, ITPR1, NLGN1, and NTRK2, whose expression levels (in addition to
HSD17B10) are also decreased in RORA1-repressed human neuronal cells and in prefrontal cortex tissues from
individuals with ASD.
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Conclusions: Findings from this study indicate that RORA transcriptionally regulates A2BP1, CYP19A1, HSD17B10, ITPR1,
NLGN1, and NTRK2, and strongly suggest that reduction of this sex hormone-sensitive nuclear receptor in the brain
causes dysregulated expression of these ASD-relevant genes as well as their associated pathways and functions which,
in turn, may contribute to the underlying pathobiology of ASD.
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Promoter microarrayBackground
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder that is characterized by deficits in social under-
standing and interactions, aberrant communication, and
repetitive, stereotyped behaviors, often with restricted
interests [1-4]. With an overall prevalence of 1 in 88 indi-
viduals in the United States [5], autism is inexplicably
biased towards males by a ratio of at least 4:1, although
some recent studies [6,7] have reported ratios closer to
2:1, depending on the population studied. The consistently
observed male bias, however, has prompted theories that
elevated fetal or neonatal testosterone levels may be a risk
factor for ASD [8], and the recent association of various
autism traits in individuals who presented prenatally with
elevated testosterone levels in amniotic fluid has sup-
ported this hypothesis [9,10]. However, the molecular and
physiological mechanism(s) that lead to elevated testoster-
one levels in individuals with ASD, both prenatally and
postnatally, remain essentially unknown.
We have recently identified a novel autism candidate
gene, retinoic acid-related (RAR) orphan receptor-alpha
(RORA) [11] which is regulated by male and female hor-
mones in a manner that may provide an explanation for
the higher testosterone levels and, possibly, sex bias in
ASD [12]. RORA is a ligand-dependent orphan nuclear
hormone receptor that, in combination with co-regulator
proteins, serves as a transcriptional regulator. Although
RORA has never before been associated with ASD, our
recent studies have demonstrated: reduced expression of
RORA in lymphoblastoid cell lines (LCL) derived from
individuals with autism [13]; increased methylation lead-
ing to reduced expression of RORA in the LCL from cases
vs. sibling controls [11]; and decreased expression of
RORA protein in the prefrontal cortex and the cerebellum
of individuals with autism [11]. Together, these results link
these molecular changes in RORA in blood-derived
peripheral cells to molecular pathology in the brain tissues
of individuals with autism.
These findings are notable because studies on the
Rora-deficient staggerer mouse model indicate that Rora
is involved in several processes potentially relevant to
autism, including Purkinje cell differentiation [14,15],
cerebellar development [16,17], protection of neuronsagainst oxidative stress [18], suppression of inflamma-
tion [19], and regulation of circadian rhythm [20]. In-
deed, the involvement of Purkinje cells and cerebellar
abnormalities as well as neuroinflammation and oxida-
tive stress in the autistic brain has been comprehensively
discussed in a consensus report on the pathological role
of the cerebellum in autism [21]. Recently, the proposed
circadian dysfunction in ASD [22,23] has also been sup-
ported by both genetic studies that have identified poly-
morphisms in “clock” (circadian regulator) genes [24] as
well as gene expression analyses that identified RORA as
one of the 15 differentially expressed circadian genes in
a phenotypic subgroup of individuals with ASD with
severe language impairment [13]. The known functions
of Rora in the mouse model thus appear to be relevant
to the observed pathological findings in humans with
ASD. Moreover, behavioral studies on the staggerer
mouse, primarily used as a model to study ataxia and
dystonia [16], show that RORA is also associated with
restricted behaviors reminiscent of autism, such as per-
severative tendencies [25], limited maze patrolling [26],
anomalous object exploration [27], and deficits in spatial
learning [28]. Although there are currently no reported
studies on the social behaviors of staggerer mice, it is
clear that RORA is associated with at least some of the
symptomatology and pathology of autism.
As a transcriptional regulator, RORA is known to bind
DNA as a monomer or as a homodimer to hormone re-
sponse elements upstream of target genes to modulate
expression of those genes. In staggerer mice that exhibit
spontaneous disruption of the Rora gene, Rora de-
ficiency has been reported to cause aberrant expression
of several genes involved in Purkinje cell differentiation
(for example, Shh), calcium-mediated signaling (for ex-
ample, Itpr1, Calb1, Cals1, Pcp4), as well as excitatory
neurotransmission at glutamatergic synapses of Purkinje
cells in the cerebellum (for example, Slc1a6, Grm1,
Pcp2) [29]. In mouse skeletal muscle, Rora influences
genes associated with lipid and carbohydrate metabo-
lism (for example, Acsl4, Cd36, Hif1a), LXR nuclear re-
ceptor signaling (for example, LXRa, Srebp-1c), and Akt
and AMPK signaling (for example, Akt2) [30]. Liver
tissues of Rora-deficient mice have been shown to
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triglyceride synthesis and storage (for example, Cidec,
Cidea, Mogat1) [31], thus demonstrating pleiotropic
effects of Rora depending on tissue type. However, little is
known about transcriptional targets of RORA in humans,
particularly in the central nervous system. We therefore
sought to identify, at the genome-wide level, putative tran-
scriptional targets of RORA in human neuronal cells, and
to validate a functionally relevant subset of targets that
may play a role in ASD. Since we have previously demon-
strated decreased RORA expression in the frontal cortex
of individuals with autism relative to that of unaffected
controls [11,12], we also investigated mRNA expression of
the confirmed RORA targets in postmortem brain tissues
of individuals diagnosed with autism in comparison with
the expression of those genes in the brain of sex-matched
and age-matched unaffected individuals.
Methods
Cell culture
The human neuroblastoma cells SH-SY5Y (ATCC,
Manassas,VA, USA) were cultured in 1:1 Modified
Eagle’s Medium (MEM) and Ham’s F12 media (MediaTech,
Manassas, VA, USA) supplemented with 15% (v/v) fetal
bovine serum (Atlanta Biologicals, Lawrenceville, GA,
USA) and 1% penicillin/streptomycin (MediaTech). Cells
were maintained at 37°C with 5% CO2, and split 1:2 every
3 or 4 days when the cells reached ~80% confluency.
For harvesting, the cells were treated with trypsin-
ethylenediamine tetraacetic acid (MediaTech) for 2 to 3
minutes to release them from the surface of the culture
flask. Complete growth medium was then added to the
flask containing suspension cells to inactivate trypsin.
Cells were transferred to a sterile centrifuge tube and
pelleted by spinning at 800 rpm for 5 minutes at 4°C and
gently washed twice with ice-cold PBS.
Frozen human brain tissues
Frozen postmortem prefrontal cortex (BA9/10) tissues
from male individuals with autism (n = 3) and from age-
matched typically developing males (n = 3) were obtained
through the Autism Tissue Program (San Diego, CA,
USA). All frozen brain tissues were preserved by the
Harvard Brain Tissue Resource Center, Harvard Medical
School. The list of human brain tissues used in this study
is shown in Additional file 1, along with information on
the age of the donor, the postmortem interval (PMI) be-
tween death and tissue collection, and the cause of death
when known.
Chromatin immunoprecipitation (ChIP)-on-chip analysis
Chromatin immunoprecipitation (ChIP) for promoter
array analysis was performed using the Millipore EZ-ChIP
Chromatin Immunoprecipitation Kit (Millipore, Billerica,MA, USA) according to the manufacturer's protocol.
Briefly, the human neuronal cell line SH-SY5Y was
cultured in complete growth medium in a T-175 flask
until ~80% confluency (approximately 1.5 × 107 cells).
The medium was then carefully removed without distur-
bing the cells. The cells were fixed with 37% formaldehyde
for exactly 10 minutes to crosslink chromatin. The
crosslinking reaction was terminated by addition of 10%
glycine, after which ice-cold PBS supplemented with
protease inhibitor cocktail was added to the culture flask
to wash and chill the cells. The crosslinked cells were
dislodged from the flask by scraping gently with a cell
scraper and then transferred to a pre-chilled centrifuge
tube. Crosslinked cells were pelleted and nuclear extrac-
tion was performed using the Active Motif Nuclear
Extract Kit (Active Motif, Carlsbad, CA, USA) according
to the manufacturer's protocol. Nuclear pellets were
resuspended in SDS Lysis Buffer and sonicated on wet
ice to shear crosslinked chromatin to 200–1,000 bp using
a Heat Systems-Ultrasonics W-380 sonicator (Heat
Systems-Ultrasonics/Misonix, Farmingdale, NY, USA) set
to 30% of maximum output power for 20 × 10 seconds
with 1-minute intervals. Sonicated chromatin was divided
into several aliquots for immunoprecipitation reactions
and stored at −80°C until use. Each immunoprecipitation
reaction was conducted using 1 μg of goat anti-RORA1
or normal goat IgG antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). Immunoprecipitated chromatin
was then reverse-crosslinked by adding 5 M NaCl to the
final concentration of 0.2 M and incubated at 65°C over-
night. DNA from the immunoprecipitated chromatin was
isolated and purified using Millipore DNA purification
columns (Millipore) and then submitted to the Genomics
Core Facility at The George Washington University for
analysis on Affymetrix human promoter tiling arrays
(Affymetrix, Santa Clara, CA, USA).
Analysis of RORA binding sites on Affymetrix promoter
tiling arrays
Purified DNA from the chromatin immunopre-
cipitated with anti-RORA1 or control IgG antibodies
was amplified using the Whole Genome Amplification
2 Kit (Sigma Aldrich, St. Louis, MO, USA) according
to the manufacturer’s protocol. The amplification prod-
uct of each immunoprecipitation reaction was purified
and hybridized on Affymetrix GeneChip Human Pro-
moter 1.0R microarrays. Probes significantly enriched
in RORA1-immunoprecipitated DNA relative to IgG-
immunoprecipitated DNA were identified using the
Partek Genomics Suite software (Partek, St. Louis, MO,
USA), as described in detail below.
The Affymetrix Human Promoter 1.0R array contains
over 4.6 × 106 probes tiled over 25,500 promoter regions of
annotated genes. Each gene promoter is thus interrogated
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DNA immunoprecipitated from SH-SY5Y cells with either
a RORA1-specific antibody or a non-specific IgG as a con-
trol was hybridized on separate chips in triplicate, and
the amount of probe hybridized to each element on the
chips was determined. Partek Genomics Suite Software was
used to analyze the intensities of the probe elements across
the promoter array using the workflow recommended by
Affymetrix for tiling arrays. In brief, the data normaliza-
tion procedures include adjusting for probe sequence,
RMA background correction, quantile normalization, and
log (base 2) transformation of intensity data. Two-way
analysis of variance was then used to determine differences
between the RORA1-co-immunoprecipitated DNA and
IgG-co-immunoprecipitated control DNA in hybridizing
to specific probes. The MAT (model-based analysis of
tiling arrays) peak-seeking algorithm [32] was subsequently
used to detect enriched regions in the RORA1-co
-immunoprecipated DNA versus IgG control samples.
Nominal P value cutoff ≤0.05 (corresponding to false dis-
covery rate (FDR) <7%), MAT score >0, minimum number
of probes for each region >10, and average length for the
ChIP fragment >600 bp were used as the peak detection pa-
rameters in this discovery phase of high-throughput screen-
ing for potential RORA targets. The microarray data from
this study have been deposited into the Gene Expression
Omnibus repository [GEO: GSE45756]. Positive MAT
scores for a specific region indicate that RORA binding is
enriched in that region relative to IgG controls. The genes
mapping to the RORA-enriched promoter regions were
identified using the gene annotation database (hg18) pro-
vided by Affymetrix. To further aid in the selection of gene
promoters for confirmation analyses, an additional level of
analysis was performed to determine the average intensity
of probes across the regions hybridizing to the RORA-
immunoprecipitated DNA relative to that hybridizing to
the control DNA. These intensities were used to calculate
the fold-change or enrichment across each gene promoter
region for binding of the RORA-immunoprecipitated
DNA over that of the IgG-precipitated DNA. Among
the RORA-enriched promoter sites, the site corresponding
to ITPR1 was used as a positive control since Itpr1 had
been identified as a transcriptional target of Rora in
mice [29]. Because the ITPR1 promoter region exhibited a
fold-change of 1.29, we used this value as a minimum
average fold-change in selecting target genes for further
confirmation.
Rationale for selection of putative target genes for
further confirmation
Of the 2,544 genes identified as putative targets of RORA
by the ChIP-on-chip analysis (see Results), we selected
ITPR1, CYP19A1, HSD17B10, A2BP1 (RBFOX1), NLGN1,
and NTRK2 for further confirmation by ChIP-quanititativePCR analyses and by functional knockdown of RORA.
Among these putative target genes, A2BP1, ITPR1, NLGN1,
and NTRK2 have been previously identified as candidate
genes for ASD [33-35]. The protein product of CYP19A1,
also known as aromatase, is involved in the enzymatic con-
version of androgen to estrogen via testosterone intermedi-
ates. Although CYP19A1 had previously been reported to
be a target of RORA in human breast cancer cell lines [36],
we recently demonstrated that its promoter region was a
site of RORA binding in a human neuronal cell line [12].
Here, we wished to further confirm CYP19A1 as a tran-
scriptional target of RORA by functional knockdown stud-
ies. Like CYP19A1, HSD17B10 also codes for an enzyme
involved in the conversion of androgen to estrogen, but via
19-hydroxyandrostenedione, 19-oxyandrostenedione and
estrone intermediates. Because of our earlier study demon-
strating significant and correlated reductions in RORA and
CYP19A1 protein levels in the autistic brain [12], we were
interested in determining whether a deficiency in RORA
could also impact this alternate biochemical pathway
through down-regulation of HSD17B10, thus potentially
reinforcing the buildup of androgen and reduction of estro-
gen in neuronal cells and tissues. The relevance of these
genes to ASD is further elaborated in the Discussion.
Prediction of RORA binding elements
Putative binding elements of RORA in the promoter
regions of A2BP1, CYP19A1, HSD17B10, ITPR1, NLGN1,
and NTRK2 were predicted using PROMO 3.0 [37,38],
JASPAR [39], and the EpiTect ChIP Search Portal of
SABiosciences (Valencia, CA, USA). For each putative
target gene, a total of three or four predicted transcription
factor binding sites within 10 kb upstream of the tran-
scription start site were selected for ChIP-quantitative
PCR analyses.
ChIP-quantitative PCR analysis
Chromatin immunoprecipitation for ChIP-quantitative
PCR analysis of RORA binding elements in the pro-
moter region of putative RORA targets was conducted
using the ChIP-IT Express Enzymatic Kit (Active Motif )
following the manufacturer’s instructions. Briefly, conflu-
ent SH-SY5Y cells (approximately 1.5 × 107 cells in a T-
175 flask) were fixed with 10% formaldehyde for exactly
10 minutes and the fixation reaction was stopped by
adding 10% glycine to the flask. The cells were washed
with 10 ml ice-cold PBS for 5 seconds, then 6 ml ice-
cold PBS supplemented with 0.5 mM (final concentra-
tion) phenylmethylsulfonylfluoride supplied in the kit
was added to the culture flask to wash and chill the cells.
The crosslinked cells were transferred from the flask to
a pre-chilled 15 ml centrifuge tube by scraping gently
with a cell scraper. Crosslinked cells were pelleted by
centrifugation for 10 minutes at 2,500 rpm (720 relative
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ice-cold Active Motif Lysis Buffer (Active Motif ). The
crosslinked cells were transferred to an ice-cold dounce
homogenizer and the nuclei were released from the cells
by douncing with a tight pestle. Optimal cell lysis was
assessed under a phase contrast microscope using a
hemacytometer. The nuclei were then transferred to an
ice-cold 1.7 ml microcentrifuge tube and pelleted by cen-
trifugation for 10 minutes at 5,000 rpm (2,400 relative
centrifugal force) at 4°C. Chromatin was then isolated
from the nuclear pellets and sheared into 150 to 1,000 bp
fragments by incubating with 10 U/ml (final concentra-
tion) Enzymatic Shearing Cocktail (Active Motif) at 37°C
for exactly 10 minutes. The enzymatic shearing reaction
was stopped by adding ethylenediamine tetraacetic acid to
a final concentration of 10 mM and chilling the reaction
tube on ice for 10 minutes. Optimal shearing was assessed
by agarose gel electrophoresis. For each ChIP reaction,
enzymatically-sheared chromatin containing ~7 to 25 μg
chromatin DNA was immunoprecipitated using 1 μg anti-
body and 25 μl Protein G Magnetic Beads (Active Motif).
The list of antibodies for ChIP analyses is shown in
Additional file 2. Immunoprecipitated chromatin was
reverse-crosslinked according to the ChIP-IT Express
Enzymatic Kit protocol and DNA was isolated and puri-
fied from the chromatin using the ChIP DNA Purifica-
tion Kit (Active Motif ).
Real-time quantitative PCR analysis was conducted
using the Applied Biosystems 7300 Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA) to
determine the enrichment of each RORA binding element
in immunoprecipitated DNA. Primers for quantitative
PCR analysis were designed using Primer3 software [40]
and were synthesized by Integrated DNA Technologies
(Coralville, IA, USA). Input DNA was diluted into five
10-fold serial dilutions and included in quantitative PCR
analyses. Relative enrichment values of RORA binding ele-
ments in each immunoprecipitated chromatin were calcu-
lated using standard curves obtained from the enrichment
of RORA binding elements in the 10-fold serial dilutions
of respective input DNA. The list of primers is shown in
Additional file 3.
Short hairpin RNA (shRNA) transfection
SH-SY5Y cells were cultured in a six-well culture plate
containing complete growth medium without antibi-
otics (approximately 2.5 × 105 cells per well) until cells
were ~70% confluent. For each well, the cells were
transfected with 2.50 μg RORA1 shRNA (Santa Cruz Bio-
technology) or 2.50 μg negative control shRNA (Santa
Cruz Biotechnology) using Lipofectamine LTX and PLUS
reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer's protocol. Briefly, shRNA (2.50 μg) was
diluted in 500 μl Opti-MEM I Reduced Serum Medium(Invitrogen) and 1.25 μl PLUS reagent was added to the
diluted shRNA solution. Lipofectamine LTX (25 μl) was
then added to the shRNA-PLUS solution, incubated
for 25 minutes at room temperature to form shRNA-
Lipofectamine-LTX-PLUS complexes, and added to the
cells. The cells were then incubated with the shRNA-
Lipofectamine-LTX-PLUS complexes at 37°C and 5% CO2
for 24 hours before harvesting. The list of shRNAs is
shown in Additional file 2.
RNA isolation and quantitative RT-PCR analysis
Quantitative RT-PCR analyses were performed as pre-
viously described [41]. Total RNA from the shRNA-
transfected cells was isolated using TRIzol (Invitrogen) and
purified using the RNeasy Mini Kit (Qiagen, Gaithersburg,
MD, USA) following the manufacturers' instructions. Hu-
man brain tissues were homogenized in the Bullet Blender
Homogenizer (Next Advance, Averill Park, NY, USA) using
nuclease-free glass beads, after which total RNA from ho-
mogenized brain tissues was isolated using the RNeasy
Mini Kit (Qiagen). A total of 1 μg purified total RNA was
used for cDNA synthesis using the iScript cDNA Synthesis
Kit (BioRad, Hercules, CA, USA) according to the manu-
facturer’s protocols. The reaction (20 μl) was incubated at
25°C for 5 minutes, followed by 42°C for 30 minutes, and
ending with 85°C for 5 minutes. After reverse transcription,
the cDNA reaction mixture was diluted to a volume of
50 μl with nuclease-free water and used as a template for
quantitative PCR analyses. Real-time PCR analyses were
conducted using the Applied Biosystems 7300 Real-Time
PCR System (Applied Biosystems). Primers for quantitative
RT-PCR analyses designed by Primer3 software are listed
in Additional file 3. The relative quantity of transcripts in
each sample was calculated using standard curves based
on the relative quantity of 18S RNA transcript in 10-fold
serial dilutions of the respective sample.
Statistical analysis
A paired, two-sided, Student’s t test was performed to
determine significance of the differences in numerical
data obtained by quantitative PCR analyses. P <0.05 was
considered statistically significant.
Hypergeometric distribution analyses [42] were used to
determine the statistical significance of enrichment in
autism candidate genes among the transcriptional targets
identified by ChIP-on-chip analysis, relative to the genes
present in AutDB [34], AutismKB [35], or a combination
of the two databases of autism-associated genes.
Pathway and gene ontology analyses
Network prediction, functional, and gene ontology ana-
lyses were accomplished using licensed Ingenuity Pathway
Analysis (IPA) and Pathway Studio7.0 software, as well
as the open-access DAVID Bioinformatics Resources 6.7
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P values were calculated using the entire set of genes in
the Ingenuity Knowledge Base as the reference set.
Results
Identification of RORA transcriptional targets using
whole-genome promoter array analysis and gene
ontology analyses
ChIP-on-chip analysis revealed that a total of 2,764 probes
(corresponding to 2,544 unique genes) were significantly
enriched in RORA-immunoprecipitated chromatin rela-
tive to IgG-immunoprecipitated chromatin (P <0.05; FDR
<7%). The complete list of gene-associated regions from
the ChIP-on-chip analyses is shown in Additional file 4.
Gene ontology analysis of this complete list of genes using
DAVID Bioinformatics Resources 6.7 shows that neuron
differentiation and development as well as axonogenesis
are significantly over-represented among biological pro-
cesses shown in Annotation cluster 1 which has a highly
significant Enrichment Score (ES) of 5.107 (Table 1). The
dataset is also significantly enriched for genes involved in
synaptic transmission and plasticity (Annotation cluster 4
with enrichment score 3.456) and post-synaptic density
(Annotation cluster 5 with enrichment score 3.176). Fur-
thermore, it is remarkable that all of genes in annotation
clusters 1 to 5 are contained in AutDB and/or AutismKB
databases. (See Additional file 5 for a full list of genes and
functions associated with annotation clusters 2 to 5.) This
is noteworthy because, although this nuclear hormone re-
ceptor is known to have pleiotropic functions in different
tissues, neurological functions are clearly enriched among
the putative transcriptional targets of RORA within the
context of a human neuronal cell line.
To further mine the dataset of potential transcriptional
targets for higher level biological functions, disorders,
and canonical pathways, we conducted network predic-
tion and functional analysis on the RORA-bound genes
using Ingenuity Pathway Analysis (IPA) software. Table 2
summarizes the functional and pathway analysis which
reveals that nervous system development and function,
neurological disease, and axonal guidance signaling are
among the top five most significantly over-represented
biological functions, disorders, and canonical pathways,
respectively, associated with the RORA-enriched gene
dataset. More detailed investigation into the specific
neurological functions associated with the genes showed
significant enrichment of genes involved in development
of the brain and nervous system, axonogenesis, cell-cell
adhesion of neurons, long-term potentiation of granule
cells, neuritogenesis, and development of the cerebellum
(Table 3). The genes associated with neurological disor-
ders/diseases were enriched for schizophrenia, Huntington’s
disease, movement disorders, dyskinesia, and seizure dis-
order, the latter three of which often present with the mostsevere subtype of ASD, which we have found to be associ-
ated with RORA deficiency [13]. Interestingly, a number of
behaviors that are often disrupted or impaired in ASD, such
as cognition, learning, circling behavior, emotional behavior,
memory and spatial learning, are also significantly over-
represented in the dataset of putative transcriptional targets
of RORA. The complete list of genes associated with each
of the biological functions, diseases/disorders, and behav-
iors described in Table 3 are provided in Additional file 6.
To determine whether the ChIP-on-chip-identified
putative targets of RORA were enriched in autism candi-
date genes, hypergeometric distribution analyses were
performed to calculate P values for over-representation
of genes from two autism gene databases (AutDB and
AutismKB) within the target gene list. The results of the
hypergeometric distribution analyses (Table 4) indicate
that autism candidate genes, identified through various
other studies, are indeed enriched among our transcrip-
tional targets.
Network prediction of selected transcriptional targets to
assess relevance to autism spectrum disorder (ASD)
We selected six potential gene targets, ITPR1, CYP19A1,
A2BP1, HSD17B10, NLGN1, and NTRK2, for confirm-
ation by independent ChIP-quantitative PCR and func-
tional analyses based on the reasons given in Methods.
The probe enrichment data and genomic locations for
these genes are shown in Table 5. Functional analysis of
these six genes using the Pathway Studio 7.0 network pre-
diction program revealed an association of these genes
with neurological disorders, including autism and ataxia,
as well as autism-related neurological functions, including
synaptogenesis, synaptic transmission, long-term potenti-
ation, learning, and memory (Figure 1). Interestingly, other
autism candidate genes, including NLGN3, NRXN1, RELN,
and GABAA, were also included in the predicted gene
network, thus supporting the investigation of our selected
genes as ASD-relevant transcriptional targets of RORA.
Confirmation of RORA binding to selected transcriptional
targets in human neuronal cells
To confirm that RORA protein binds to the promoter
region of these six potential transcriptional targets, we
conducted ChIP using anti-RORA1 or nonspecific IgG
antibody, followed by quantitative PCR analysis to deter-
mine the enrichment of RORA binding sites in the
respective promoter regions of the selected genes. Figure 2
shows that RORA binding sites in the promoter region(s)
of each of these potential targets were significantly
enriched in chromatin samples immunoprecipitated by
anti-RORA1 antibody relative to IgG-immunoprecipitated
chromatin, indicating that RORA protein indeed binds to
promoter regions of A2BP1, CYP19A1, HSD17B10, ITPR1,
NLGN1, and NTRK2.
Table 1 Top annotation cluster from gene ontology analysis of 2,544 potential transcriptional targets of RORA
Annotation cluster 1: enrichment score 5.107
GO term Count P Value Benjamini* Genes
GO:0030182-neuron
differentiation
35 1.52E-08 3.56E-05 RAB3A, CDK5R1, ADORA2A, PAX3, RORA, RTN1, EPHB2, ARX, ATP2B2, BDNF, SLC1A3, LAMB2, CD44, CXCR4,
ANK3, DMD, ROBO3, LHX8, LMX1B, MDGA2, PTPRR, NTNG1, RPGRIP1, NUMBL, SOD2, PTPN11, CTNNA2,
SLITRK1, NTRK1, NTRK2, FOXG1, CNTN4, CACNA1F, CUX1, NTM
GO:0048666-neuron
development
28 2.96E-07 3.48E-04 RAB3A, CDK5R1, ADORA2A, EPHB2, ARX, ATP2B2, BDNF, SLC1A3, LAMB2, CD44, ANK3, CXCR4, DMD, ROBO3,




22 1.86E-06 1.45E-03 RAB3A, CDK5R1, NTNG1, PTPN11, CTNNA2, EPHB2, NUMBL, ARX, SLITRK1, ATP2B2, DAB2, BDNF, SLC1A3,
LAMB2, CXCR4, ANK3, LAMA5, FOXG1, CNTN4, ROBO3, CACNA1F, FN1
GO:0000902-cell morphogenesis 27 2.53E-06 1.48E-03 RAB3A, CDK5R1, ADORA2A, EPHB2, ARX, ATP2B2, BDNF, DAB2, SLC1A3, LAMB2, ANK3, CXCR4, DMD, MKKS,




28 6.15E-06 2.88E-03 RAB3A, CDK5R1, ADORA2A, EPHB2, ARX, ATP2B2, DAB2, BDNF, SLC1A3, LAMB2, ANK3, CXCR4, DMD, OBSL1,




21 7.30E-06 2.14E-03 RAB3A, CDK5R1, ADORA2A, NTNG1, PTPN11, CTNNA2, EPHB2, NUMBL, ARX, SLITRK1, BDNF, LAMB2, CXCR4,
ANK3, LAMA5, DMD, FOXG1, MKKS, CNTN4, ROBO3, CACNA1F
GO:0048667-cell morphogenesis
involved in neuron differentiation
19 1.01E-05 2.63E-03 RAB3A, CDK5R1, NTNG1, PTPN11, CTNNA2, EPHB2, NUMBL, ARX, SLITRK1, ATP2B2, BDNF, SLC1A3, LAMB2,
CXCR4, ANK3, FOXG1, CNTN4, ROBO3, CACNA1F
GO:0048812-neuron projection
morphogenesis
19 1.31E-05 3.07E-03 RAB3A, CDK5R1, ADORA2A, NTNG1, PTPN11, CTNNA2, EPHB2, NUMBL, ARX, SLITRK1, BDNF, LAMB2, CXCR4,
ANK3, DMD, FOXG1, CNTN4, ROBO3, CACNA1F
GO:0030030-cell projection
organization
26 1.39E-05 2.96E-03 MTSS1, RAB3A, CDK5R1, DNAH9, ADORA2A, EPHB2, ARX, ATP2B2, BDNF, LAMB2, CD44, ANK3, CXCR4, DMD,
MKKS, ROBO3, FGD3, NTNG1, CTNNA2, PTPN11, NUMBL, SLITRK1, LAMA5, FOXG1, CNTN4, CACNA1F
GO:0032990-cell part
morphogenesis
21 1.40E-05 2.73E-03 RAB3A, CDK5R1, ADORA2A, NTNG1, PTPN11, CTNNA2, EPHB2, NUMBL, ARX, SLITRK1, BDNF, LAMB2, CXCR4,
ANK3, LAMA5, DMD, FOXG1, MKKS, CNTN4, ROBO3, CACNA1F
GO:0031175-neuron projection
development
20 4.65E-05 6.80E-03 RAB3A, CDK5R1, ADORA2A, NTNG1, PTPN11, CTNNA2, EPHB2, NUMBL, ARX, SLITRK1, BDNF, LAMB2, CD44,
CXCR4, ANK3, DMD, FOXG1, CNTN4, ROBO3, CACNA1F
GO:0007409-axonogenesis 17 4.98E-05 6.86E-03 RAB3A, CDK5R1, NTNG1, PTPN11, CTNNA2, EPHB2, NUMBL, ARX, SLITRK1, BDNF, LAMB2, CXCR4, ANK3,
FOXG1, CNTN4, ROBO3, CACNA1F
GO:0007411-axon guidance 9 7.12E-03 2.67E-01 ARX, CDK5R1, BDNF, CXCR4, ANK3, FOXG1, CNTN4, ROBO3, EPHB2





















Table 2 Top five biological functions, disorders, and canonical pathways associated with 2,544 potential
transcriptional targets of RORA
Biological functions, disorders, and pathways P value Number of molecules
Physiological system development and function
Organismal survival 3.56E-08 to 6.82E-04 305
Nervous system development and function 5.83E-08 to 4.28E-03 344
Tissue morphology 5.83E-08 to 4.72E-03 419
Cardiovascular system development and function 8.89E-08 to 4.72E-03 268
Embryonic development 9.01E-08 to 4.72E-03 370
Diseases and disorders
Hereditary disorder 8.09E-06 to 1.56E-03 204
Neurological disease 8.09E-06 to 4.72E-03 292
Psychological disorders 8.09E-06 to 8.09E-06 107
Cancer 1.65E-05 to 4.77E-03 731
Hematological disease 1.65E-05 to 4.67E-03 166
Top canonical pathways Ratio
Superpathway of inositol phosphate compounds 4.97E-04 37/227
Production of nitric oxide and reactive oxygen species in macrophages 1.29E-03 35/210
Axonal guidance signaling 2.47E-03 69/468
3-phosphoinositide biosynthesis 2.52E-03 29/175
Small cell lung cancer signaling 2.60E-03 17/89
These data were obtained using Ingenuity Pathway Analysis software. P values were calculated using Fisher's exact test, which was performed using the entire set
of genes within the Ingenuity Knowledge Base as the reference set.
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transcriptional targets in human neuronal cells
To further validate that RORA regulates expression of
A2BP1, CYP19A1, HSD17B10, ITPR1, NLGN1, and
NTRK2, and to examine whether reduction of RORA
expression leads to reduced expression of these selected
RORA transcriptional targets, shRNA-mediated knock-
down of RORA was performed in SH-SY5Y cells using
RORA1 shRNA, and quantitative RT-PCR analyses were
conducted to measure expression of RORA1 and the
potential targets. Expression of RORA1 in SH-SY5Y cells
was significantly down-regulated by approximately 50% in
comparison with cells transfected with negative control
shRNA, indicating that shRNA-mediated knockdown of
RORA1 was successful. Notably, expression of all selected
RORA transcriptional targets was significantly reduced
(Figure 3), indicating that expression of these genes is
regulated by RORA and that these genes indeed are
RORA transcriptional targets in human neuronal cells. As
a negative control, the expression level of GAPDH, which
is not a transcriptional target of RORA, is unaffected by
transfection of the SH-SY5Y cells with RORA1 shRNA.
Expression of transcriptional targets of RORA is relatively
reduced in the frontal cortex of individuals with autism in
comparison with age-matched controls
We have previously reported reduction of RORA tran-
script and/or protein in four independent cohorts usingLCL as well as tissues from the prefrontal cortex and the
cerebellum of individuals diagnosed with autism [11-13].
To examine whether RORA reduction in the brain of in-
dividuals with autism may be associated with aberrant
expression of the transcriptional targets identified in this
study, a pilot study involving quantitative RT-PCR ana-
lysis of frozen postmortem prefrontal cortex tissues from
individuals with autism (n = 3) and age-matched con-
trols (n = 3) was performed. As shown in Table 6, the
average expression of each of the six gene targets in the
combined cases is reduced relative to the average ex-
pression levels of the respective genes in the combined
controls, although the P values (all P >0.05) indicate that
the differences are not statistically significant.
Discussion
Based on reduced expression of RORA in LCL and in
postmortem brain tissues of individuals with ASD versus
unaffected controls, coupled with its known functions in
cerebellar development and neuroprotection against in-
flammation and oxidative stress in mice, we postulated
that this nuclear hormone receptor may be responsible
for at least some of the pathobiology associated with
ASD. In particular, our recent finding that RORA speci-
fically binds the promoter region of aromatase, whose
protein expression in the human brain is highly corre-
lated with that of RORA, suggests a molecular explan-
ation for the increased levels of testosterone observed in
Table 3 Top neurological diseases, disorders, and
behaviors associated with the 2,544 potential
transcriptional targets of RORA
Function annotation (number of molecules) P value
Nervous system development and function
Quantity of neurons (67) 5.83E-08
Development of brain (102) 9.01E-08
Morphology of nervous system (161) 3.96E-07
Morphology of nervous tissue (118) 5.44E-07
Development of central nervous system (122) 1.50E-06
Axonogenesis (43) 1.68E-05
Morphology of nerves (30) 7.32E-05
Cell-cell adhesion of neurons (6) 1.48E-04
Morphology of central nervous system (98) 1.90E-04
Morphology of rhombencephalon (35) 2.41E-04
Quantity of sensory neurons (19) 2.81E-04
Development of nerves (19) 2.81E-04
Abnormal morphology of neurons (51) 2.85E-04
Morphology of neurons (55) 3.37E-04
Antinociception (13) 3.84E-04
Development of neurons (37) 3.98E-04
Morphology of brain (88) 4.40E-04
Development of interneurons (7) 4.56E-04
Migration of neurons (46) 4.79E-04
Abnormal morphology of cerebellum (21) 5.58E-04
Development of metencephalon (24) 5.88E-04
Loss of neurons (29) 8.01E-04
Long-term potentiation of granule cells (4) 8.18E-04
Abnormal morphology of cranial nerve (19) 8.60E-04
Neuritogenesis (83) 1.11E-03
Development of cerebellum (23) 1.22E-03
Development of forebrain (45) 1.26E-03
Fasciculation of nervous tissue (9) 1.34E-03
Abnormal morphology of granule cells (12) 1.42E-03
Development of globus pallidus (3) 1.56E-03
Activation of hippocampus (3) 1.56E-03
Abnormal morphology of hair cells (9) 1.84E-03
Morphogenesis of neurites (58) 1.85E-03
Adhesion of neuronal cells (14) 1.88E-03
Abnormal morphology of outer hair cells (6) 2.01E-03
Sensory system development (23) 2.09E-03
Development of rhombencephalon (28) 2.15E-03
Chemotaxis of granule cells (4) 2.23E-03
Guidance of axons (31) 2.24E-03
Morphology of mechanosensory neurons (10) 2.49E-03
Cell viability of neurons (39) 2.51E-03
Analgesia (18) 2.62E-03
Synaptic transmission of cerebral cortex cells (11) 3.03E-03
Memory (39) 3.52E-03
Table 3 Top neurological diseases, disorders, and
behaviors associated with the 2,544 potential
transcriptional targets of RORA (Continued)
Neurotransmission (71) 3.75E-03
Development of cranial nerve (11) 3.79E-03




Huntington's Disease (116) 4.09E-04
Movement Disorders (183) 9.11E-04
Dyskinesia (118) 1.27E-03
Neurological signs (120) 1.45E-03
Familial transthyretin amyloidosis (3) 1.56E-03
Seizure disorder (60) 3.92E-03






Circling behavior (12) 1.11E-03
Emotional behavior (42) 3.04E-03
Memory (39) 3.52E-03
Spatial learning (33) 4.23E-03
These data were obtained using Ingenuity Pathway Analysis software. P values
were calculated using Fisher's exact test, which was performed using the
entire set of genes within the Ingenuity Knowledge Base as the reference set.
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that downregulation of aromatase would lead to a buildup
of its substrate, testosterone, with a corresponding reduc-
tion in estrogen synthesis. Moreover, the downregulation
of RORA expression in response to androgen and upre-
gulation in response to estrogen suggest a mechanism for
the introduction of sex bias in ASD.
As a nuclear hormone receptor, RORA, in combination
with various co-regulator proteins, can potentially regulate
the transcription of a large number of gene targets. This
study was therefore conducted in order to identify add-
itional transcriptional targets of RORA, specifically within
the context of a human neuronal cell model. To our know-
ledge, this is the first ChIP-on-chip study directed towards
the comprehensive identification of transcriptional targets
of RORA at the genome-wide level in any species. Conse-
quently, in this pilot study aimed at discovery of genes that
may be regulated by RORA, we chose to use less stringent
P values (P ≤0.05; FDR <7%) for identification of RORA-
enriched regions in order to capture as many potential
gene targets of RORA as possible. Not surprisingly, our
ChIP-on-chip analysis identified 2,764 promoter regions
Table 4 Hypergeometric distribution analysis results to determine enrichment of autism candidate genes from AutDB
and AutismKB









AutDB (SFARI gene) 328 25,500 2,544 49 0.0028
AutismKB (syndromic + non-syndromic) 3,050 25,500 2,544 426 <0.001
AutDB + AutismKB 3,158 25,500 2,544 438 <0.001
For the hypergeometric distribution analyses, the total number of general markers (that is, the population) is the number of genes (25,500) whose promoter
regions are represented on the array, and the total number of selected markers is the number of unique genes (2,544) identified as targets of RORA by the
ChIP-on-chip analysis. The total interesting markers are the number of autism candidate genes in the respective or combined databases, and the number of
selected interesting markers are the genes within our dataset that overlap with those in either or the combined databases.
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http://www.molecularautism.com/content/4/1/14enriched for RORA binding sites, which corresponded to
2,544 unique genes. Interestingly, gene ontology analysis of
this complete set of putative target genes revealed a strik-
ingly high enrichment in genes associated with neuron
differentiation and development, neuron projection mor-
phogenesis, axonogenesis, and axon guidance in the top
functional annotation cluster (enrichment score 5.107). In-
triguingly, all of the genes associated with these processes
are listed in the AutDB (SFARI Gene) and/or AutismKB
databases of autism-associated genes, indicating relevance
of our target gene set to ASD. Two additional highly
significant functional annotation categories of genes are re-
lated to synaptic transmission and plasticity (enrichment
score 3.456) and postsynaptic density (enrichment score
3.176). Again, all of the genes in both annotation categories
are contained within one of the two aforementioned data-
bases. The statistically significant enrichment of autism
candidate genes within our dataset of genes identified by
ChIP-on-chip analysis was also confirmed by hypergeo-
metric distribution analyses which used the number of
genes in either or both of the autism databases as the total
number of interesting markers and the overlap between
the genes in our dataset (that is, the selected markers) and
the genes in either database as the number of selectedTable 5 Enrichment data and genomic location of the RORA-b














A2BP1 (RBFOX1) RNA binding protein,
fox-1 homolog
12.86 0.009 <








kinase, receptor, type 2
6.72 0.044 <
FDR false discovery rate, G intensity of probes hybridized with DNA fragments imm
arrays, R intensity of probes hybridized with DNA fragments immunoprecipitated winteresting markers. The total number of annotated genes
on the microarray represents the total number of general
markers (that is, the population).
Biological network and pathway analysis using Ingenu-
ity Pathway Analysis software further revealed that these
potential transcriptional targets of RORA are signifi-
cantly associated with nervous system development and
function including development of cortex and cerebel-
lum, axonogenesis, adhesion of neuronal cells, neuronal
migration, neuritogenesis, neurotransmission, and syn-
aptic density, all of which have been associated with
autism [45-50]. It is also noteworthy that neurological
disorders known to be co-morbid with autism, including
schizophrenia [51,52], movement disorder [53-57], and
seizure disorder [58-61], were also over-represented
among the genes in our dataset. Of particular relevance
to behavioral deficits in ASD, genes related to cognition,
learning, repetitive behaviors (for example, circling),
memory, and spatial learning are also associated with
these potential targets of RORA.
Among the selected targets of RORA investigated in
this study, we confirmed ITPR1 and CYP19A1 as tran-
scriptional targets in human neuronal cells by both
















5 1.29 chr3 (+) 4,724,792 2,804 71
5 11.86 chrX (−) 53,483,92 1,723 42
5 1.29 chr16 (+) 7,315,418 2,636 68
5 3.27 chr3 (+) 174,777,672 639 18
5 1.61 chr15 (−) 49,415,636 2,111 54
7 2.17 chr9 (+) 86,412,498 966 21
unoprecipitated with nonspecific IgG, MAT model-based analysis of tiling
ith anti-RORA antibody, T t-statistic.
Figure 1 Pathway analysis of selected potential transcriptional targets of RORA. A biological network was created using the Pathway
Studio 7.0 program to identify biological functions and disorders associated with potential RORA transcriptional targets selected for confirmation
(that is, ITPR1, CYP19A1, A2BP1, HSD17B10, NLGN1, and NTRK2 which are highlighted with a blue halo).
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http://www.molecularautism.com/content/4/1/14RORA with shRNA. As mentioned earlier, both genes
had been implicated as targets of RORA by earlier
studies with Rora-deficient mice [29] as well as in hu-
man breast cancer [36]. Our current study, however, also
reveals four novel transcriptional targets of RORA, thus
expanding the repertoire of genes and pathways that
may be impacted by RORA deficiency in humans. These
novel target genes are A2BP1 (RBFOX1), HSD17B10,
NLGN1, and NTRK2. Furthermore, our pilot study exa-
mining the expression of these six transcriptional targets
of RORA in postmortem brain tissues from individuals
with ASD and that of age-matched controls shows an
average reduction of all targets in the autism samples, al-
though the differences between combined cases and
combined controls were not statistically significant, all
exhibiting P >0.05. Surprisingly, the least significant
differences in average expression levels were observed
for RORA and CYP19A1. Inasmuch as we had previously
detected significant differences (P <0.05) between the
protein expression levels of both RORA and CYP19A1
in the frontal cortex of 22 cases versus 12 controls by
confocal immunofluorescence analyses [12], we suggest
that the lack of statistical significance for reduced
expression of these two transcripts as well as the other
targets in this study is probably due to the limitation in
sample size (n = 3 for each group) coupled with the nat-
ural variability of gene expression among the individuals.Nevertheless, the data from this limited sampling of
cases and controls suggest a trend towards reduced ex-
pression of transcriptional targets in autism brain tissues
exhibiting reduced RORA. As discussed below, an inde-
pendent review of the literature revealed that these six
RORA targets were reliably associated with autism.
Relevance of A2BP1, CYP19A1, HSD17B10, ITPR1, NLGN1,
and NTRK2 to the pathobiology of autism
A2BP1 (ataxin 2-binding protein 1), also known as
RBFOX1, is an RNA-binding protein that regulates
neuron-specific alternative splicing [62]. Several studies,
including genetic and gene expression analyses, have
established the link between this gene and autism. Using
fluorescent in situ hybridization and quantitative PCR
analyses, Martin and colleagues found a cryptic deletion
of the A2BP1 gene in a female with autism, epilepsy, and
global development delay [33]. Reduction of the A2BP1
transcript level was also observed in the lymphocytes of
this individual, suggesting that the deletion causes aber-
rant expression of this gene in this autism case. By geno-
typing 27 SNPs across this gene in 206 parent–child
trios, they identified two regions exhibiting a nominal
association with autism. Moreover, a recent noise-
reduction genome-wide association study (GWAS) of
two autism GWAS datasets (with 597 and 696 families)
from the Autism Genetic Resource Exchange revealed
Figure 2 Chromatin immunoprecipitation-quantitative PCR of RORA transcriptional targets. Chromatin immunoprecipitation followed by
quantitative PCR analysis was conducted to determine whether RORA protein binds to A2BP1, CYP19A1, HSD17B10, ITPR1, NLGN1, and NTRK2
promoters. Chromatin was isolated from SH-SY5Y cells and immunoprecipitated with anti-RORA1 or IgG antibody. DNA was purified from the
immunoprecipitated chromatin and quantitative real-time PCR analysis (n = 3) was performed to determine the enrichment of each RORA
binding element in the promoter region of the selected potential RORA targets. Error bars indicate standard error of the mean. * P <0.05;
** P <0.01; #undetectable.
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http://www.molecularautism.com/content/4/1/141,535 significant linkage disequilibrium blocks overlapping
431 genes [63]. Interestingly, regions in the A2BP1 gene
were identified among the most significant linkage dis-
equilibrium blocks (P = 3.6×10-5). Furthermore, Voineagu
and colleagues also conducted transcriptomic analysis of
postmortem frontal and temporal cortex tissues from 19
individuals with autism and 17 controls using microarrays
[64]. They found that A2BP1 expression was significantly
reduced in both frontal and temporal cortex tissues from
individuals with autism relative to controls. Using high-
throughput RNA sequencing and semi-quantitative RT-
PCR analyses, they also demonstrated that splicing of
A2BP1-dependent alternative exons in the brain of indi-
viduals with autism was dysregulated [64], suggesting that
aberrant expression of A2BP1 results in dysregulation of
alternative splicing in autism. Findings from several copy
number variation (CNV) studies [65-70] and linkagestudies [71-75] have also reported that A2BP1 is associ-
ated with autism. Aside from its association with ASD, re-
cent studies on the physiological function of A2BP1/
RBFOX1 demonstrate its involvement in synaptic trans-
mission and neuronal excitation [76] as well as its role in
the regulation of transcriptional networks involved in
neuronal development [77].
CYP19A1 encodes aromatase, a key enzyme that
converts androstenedione to estrone and testosterone to
estradiol. Although its neuronal function is most often
associated with the regulation of reproductive behaviors
through the sex hormones, more recent studies have
revealed unexpected functions of aromatase in the brain,
including neurogenesis, neuronal differentiation, synap-
tic activity and plasticity, and protection against oxida-
tive stress [50,78-82]. Another interesting observation is
the colocalization of aromatase with oxytocin in several
Figure 3 Quantitative RT-PCR analysis of RORA short hairpin RNA-transfected SH-SY5Y cells. SH-SY5Y cells were transfected with RORA1
short hairpin RNA (shRNA) or negative control shRNA for 24 hours and quantitative RT-PCR analysis (n = 3) was performed to determine
expression of RORA1 and potential transcriptional targets in the transfected cells. GAPDH was included as a negative control. Error bars indicate
standard error of the mean. *P <0.05, **P <0.01.
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Table 6 Quantitative RT-PCR analysis of post-mortem brain tissues from individuals with autism
Sample comparison
(A vs. C)
Age (A, C) RORA CYP19A1 ITPR1 A2BP1
Control Autistic A/C Control Autistic A/C Control Autistic A/C Control Autistic A/C
5144A vs. 5251C 20, 19 6.4 2.0 0.316 1.7E-04 5.2E-05 0.307 127.7 70.8 0.554 553.1 105.3 0.190
5173A vs. 5873C 30, 28 38.4 25.4 0.661 1.2E-02 5.9E-03 0.487 246.4 27.3 0.111 830.1 74.2 0.089
6337A vs. 5718C 22, 22 7.9 0.4 0.046 7.7E-06 1.0E-07 0.013 217.4 176.3 0.811 246.0 64.6 0.263
Average ratio (A/C) 17.6 9.3 0.527 4.1E-03 2.0E-03 0.484 197.2 91.5 0.464 543.1 81.4 0.150
P value (unpaired t test) 0.562 0.660 0.137 0.052
HSD17B10 NLGN1 NTRK2
Control Autistic A/C Control Autistic A/C Control Autistic A/C
5144A vs. 5251C 20, 19 128.7 15.7 0.122 178.3 23.8 0.133 3218.9 544.6 0.169
5173A vs. 5873C 30, 28 126.3 41.1 0.325 255.3 44.9 0.176 2600.1 1077.2 0.414
6337A vs. 5718C 22, 22 47.6 39.2 0.824 84.8 61.5 0.725 929.8 1265.1 1.361
Average ratio (A/C) 100.9 32.0 0.317 172.8 43.4 0.251 2249.6 962.3 0.428
P value (unpaired t test) 0.069 0.062 0.147
Gene expression in brain tissues from individuals with autism (indicated by ’A’) was compared with that in controls (indicated by ’C’). The numbers preceding ‘A’
or ‘C’ identify specific individuals whose brains were donated to the Autism Tissue Program (San Diego, CA, USA). Total RNA was isolated and purified from frozen
post-mortem prefrontal cortex tissues from individuals with autism (n = 3) and the controls (n = 3). Quantitative RT-PCR analyses (in triplicate) were performed to
measure expression of RORA and that of six transcriptional targets. The transcript levels of each gene were calculated using standard curves obtained from
relative 18S expression in 10-fold serial dilutions of each sample. The numbers highlighted in bold-face type indicate down-regulation of gene expression in
autism brain tissues relative to that in respective matched controls. The P values are from unpaired t tests of the expression data from the combined cases versus
that of the combined controls.
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cleus of the hypothalamus and the zona incerta, which
suggests a role for this gene in oxytocinergic neurons in
the limbic system [83], which may have implications for
social cognition. CYP19A1 has also been associated with
autism by genetic studies. Allen-Brady and colleagues
conducted genome-wide screening of 70 families (192
individuals with autism and 461 unaffected relatives)
and identified three regions shown to be highly signifi-
cant in the linkage analysis [84]. Interestingly, one of the
three regions is 15q21.1-15q22.2 (heterogeneity loga-
rithm (base 10) of the odds = 5.31) where the CYP19A1
gene is located. Moreover, Chakrabarti and colleagues
studied SNPs in 68 candidate genes for autism to identify
common genetic variations associated with autistic traits
and Asperger syndrome, a high-functioning subgroup of
autism. A case–control association analysis of individuals
with Asperger syndrome (n = 174) revealed regions in 14
genes, including CYP19A1, that showed a nominally sig-
nificant association with Asperger syndrome [85].
HSD17B10 encodes 3-hydroxyacyl-CoA dehydrogenase
type-2, a mitochondrial enzyme involved in mitochondrial
integrity and oxidation of fatty acids and steroids. As men-
tioned earlier, like CYP19A1, HSD17B10 is involved in the
conversion of androgens to estradiol via androstenedione
and estrone intermediates. A reduction in HSD17B10
would thus be expected to lead to increased androgen and
reduced estrogen, either of which may have serious conse-
quences for brain development [86]. Indeed, reduced
expression of HSD17B10 causes X-linked mental retard-
ation, choreoathetosis, language impairment, and abnormalbehavior [87-89]. These associated disorders are particu-
larly interesting since we have identified RORA deficiency
(specifically, reduced expression) in the phenotypic sub-
type of ASD associated with severe language impairment
[13]. Using chromosome microarray analysis, Edens and
colleagues reported duplications involving Xp11.22-
p11.23, a region where HSD17B10 gene is located, in two
females with autism and epilepsy [90].
ITPR1 encodes inositol 1,4,5-triphosphate receptor
type 1, a ligand-gated ion channel that is activated by
cytosolic calcium and inositol triphosphate, and that is
involved in synaptogenesis and formation of dendritic
contacts [91]. Computational modeling also suggests
that the biochemical and biophysical properties of ITPR1
coupled with its high density and lower sensitivity to IP3
in cerebellar Purkinje cells are critical to its postulated
role in long-term depression [92]. With respect to ASD,
transcriptomic analysis of frontal and temporal cortex
tissues from 16 individuals with autism and 16 controls
revealed down-regulation of ITPR1 [64]. Bremer and col-
leagues used high-resolution whole genome array-based
comparative genomic hybridization to screen 223 indi-
viduals with autism to identify gene dose alterations as-
sociated with autism susceptibility. They found regions
in chromosome 3p25.3, where ITPR1 is located, signifi-
cantly enriched in individuals with autism [93]. Another
CNV study of 1,124 families, each of which included a
single proband, his/her unaffected parents and, in most
cases, an unaffected sibling, revealed as many as 234
CNV regions in several genes, including ITPR1, to be as-
sociated with autism [69]. Moreover, Levy and colleagues
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hort of families with a single affected child and at least
one unaffected sibling. Among significant regions identi-
fied to be de novo CNVs were regions containing the
ITPR1 gene [94].
NLGN1 encodes neuroligin-1, a neuronal cell surface
adhesion molecule that interacts with neurexin mole-
cules. NLGN1 is involved in formation and remodeling
of synapses in the central nervous system [95]. In
addition to synaptogenesis, a recent study has also dem-
onstrated a role for NLGN1, acting together with
NRXN1β, in neuritogenesis and the formation of neu-
ronal circuits upon activation of the fibroblast growth
factor receptor-1 [96]. In the context of ASD, Glessner
and colleagues conducted a whole-genome CNV analysis
of 859 individuals with autism and 1,409 typically deve-
loping children of European ancestry who were geno-
typed with ~550,000 SNP markers to comprehensively
identify CNVs conferring susceptibility to autism [97].
Positive findings were evaluated in an independent co-
hort of 1,336 individuals with autism and 1,110 controls
of European ancestry. Interestingly, a CNV region in the
NLGN1 gene was significantly enriched in individuals
with autism. Moreover, a family-based association ana-
lysis of 100 families with autism found a modest signi-
ficant association at a region in NLGN1 gene [98]. AFigure 4 Possible downstream consequences of deregulation of the s
summarizes findings from this study. ChIP, chromatin immunoprecipitationhigh-density SNP, genome-wide linkage study also showed
that the chromosomal region 3q26.31-q27.3 was signifi-
cantly associated with autism [99]. Deletion of this gene
was also reported to cause impaired spatial memory and
increased repetitive behavior [100].
NTRK2 encodes neurotrophic tyrosine kinase receptor
type 2 (also known as TRKB) that is a catalytic receptor
for several neurotrophins, including BDNF, NT4, and
NT3. NTRK2 is involved in axon guidance signaling as
well as synapse formation and plasticity [101-104]. Its
role in ASD is implicated by genetic association analysis
of 146 children with autism and 50 typically developing
controls which identified six SNPs and multiple haplo-
types in the NTRK2 gene [105]. This study also showed
that BDNF levels were significantly increased in children
with autism relative to that in controls, supporting a role
of NTRK2/BDNF signaling as a susceptibility factor for
the disorder.
Study limitations and future directions
Because little is known with regard to transcriptional
targets of RORA, particularly in human neuronal cells,
this ChIP-on-chip analysis was undertaken as a discov-
ery tool to screen for potential transcriptional targets at
the genome-wide level. As a result, we used a less strin-
gent P-value of 0.05 as a filter to select probes enrichedix confirmed transcriptional targets of RORA. This figure
; qPCR, quantitative PCR.
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tiple testing (which is not part of the standard Partek
analytical workflow for tiling arrays). However, all of the
regions identified using P ≤0.05 are retained in the
dataset even after imposing FDR ≤7%. Thus, although
the list of 2,544 genes that are identified as putative
targets of RORA should be interpreted with caution
pending independent validation, we suggest that this list
may be used as a basis for hypothesis generation with re-
gard to the genes, pathways and functions that may be
impacted by RORA deficiency. Another caveat is that
the list of RORA targets does not replicate all of the sev-
eral targets identified in the mouse cerebellum by ChIP-
quantitative PCR analyses [29] other than ITPR1. We do
not know the precise reason for this difference, but it is
possible that the target selection may be a function of
the specific tissues and cell types as well as species, since
the mouse targets were identified in primary cerebellar
cells, and the human targets were identified in the
SH-SY5Y human neuroblastoma cell line. Indeed, co-
regulator availability is also tissue-specific, and transcrip-
tional regulation by RORA requires association with
gene-specific and tissue-specific co-regulator proteins, thus
adding another layer of complexity to target selection.
Another potential complication is the possibility that
target selection may be directed by circadian rhythm, as
RORA is a regulator of the circadian cycle. Thus, it would
be interesting to conduct ChIP-on-chip analysis on cells
synchronized according to stage in the circadian cycle.
Finally, as noted earlier, although the average expression
levels of the RORA targets were reduced in the frontal
cortex of individuals with ASD relative to that of controls
as expected, the differences were not statistically signifi-
cant. Notably, the protein expression levels of the genes
exhibiting the least significant expression differences (that
is, highest P values) in this study, RORA and CYP19A1,
were found to be significantly different in our previous
study in which 12 autism tissue samples were compared
with 22 controls [12], thus emphasizing the need for an
expanded investigation of RORA targets involving add-
itional brain tissues from individuals with ASD and con-
trols, including samples from different brain regions.
In summary, using a high-throughput genome-wide
method for identifying potential transcriptional targets of
RORA followed by independent validation of six targets
with functional relevance to ASD, we have demonstrated
that RORA deficiency can lead to a cascade of transcrip-
tional deregulation that impacts a number of genes known
to be associated with ASD. Figure 4 summarizes the prin-
cipal findings from this study.
Conclusions
Using ChIP-on-chip analyses, we identify at the genome-
wide level over 2,500 potential transcriptional targets ofRORA, a nuclear hormone receptor, and confirm six of
these targets (four of them novel with respect to regula-
tion by RORA) in human neuronal cells by ChIP-
quantitative PCR and functional analyses. Moreover, we
demonstrate that the transcript levels of these target
genes are reduced in the postmortem frontal cortex of
autistic males who exhibit reduced RORA expression
relative to that of control males, further implicating
RORA as an upstream regulator of these genes in hu-
man brain. The significance of these findings is the like-
lihood that any mechanism that contributes to reduced
RORA expression, including elevated levels of male hor-
mones [12] and epigenetic modifications that may be the
result of as yet unknown environmental factors [11],
may lead to increased risk for autism based on the aber-
rant transcription of downstream targets of RORA,
which we show are significantly enriched for autism can-
didate genes based on hypergeometric distribution ana-
lyses of our dataset in comparison with established
databases of autism genes.
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